Cargando…

Safety of research bronchoscopy with BAL in stable adult patients with cystic fibrosis

Data on adverse events from research bronchoscopy with bronchoalveolar lavage (BAL) in patients with cystic fibrosis (CF) is lacking. As research bronchoscopy with BAL is useful for isolation of immune cells and investigation of CF lung microbiome, we sought to investigate the safety of bronchoscopy...

Descripción completa

Detalles Bibliográficos
Autores principales: Aridgides, Daniel, Dessaint, John, Atkins, Graham, Carroll, James, Ashare, Alix
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7822334/
https://www.ncbi.nlm.nih.gov/pubmed/33481845
http://dx.doi.org/10.1371/journal.pone.0245696
_version_ 1783639611311915008
author Aridgides, Daniel
Dessaint, John
Atkins, Graham
Carroll, James
Ashare, Alix
author_facet Aridgides, Daniel
Dessaint, John
Atkins, Graham
Carroll, James
Ashare, Alix
author_sort Aridgides, Daniel
collection PubMed
description Data on adverse events from research bronchoscopy with bronchoalveolar lavage (BAL) in patients with cystic fibrosis (CF) is lacking. As research bronchoscopy with BAL is useful for isolation of immune cells and investigation of CF lung microbiome, we sought to investigate the safety of bronchoscopy in adult patients with CF. Between November 2016 and September 2019, we performed research bronchoscopies on CF subjects (32) and control subjects (82). Control subjects were nonsmokers without respiratory disease. CF subjects had mild or moderate obstructive lung disease (FEV(1) > 50% predicted) and no evidence of recent CF pulmonary exacerbation. There was no significant difference in the age or sex of each cohort. Neither group experienced life threatening adverse events. The number of adverse events was similar between CF and control subjects. The most common adverse events were sore throat and cough, which occurred at similar frequencies in control and CF subjects. Fever and headache occurred more frequently in CF subjects. However, the majority of fevers were seen in CF subjects with FEV(1) values below 65% predicted. We found that CF subjects had similar adverse event profiles following research bronchoscopy compared to healthy subjects. While CF subjects had a higher rate of fevers, this adverse event occurred with greater frequency in CF subjects with lower FEV(1). Our data demonstrate that research bronchoscopy with BAL is safe in CF subjects and that safety profile is improved if bronchoscopies are limited to subjects with an FEV(1) > 65% predicted.
format Online
Article
Text
id pubmed-7822334
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-78223342021-01-29 Safety of research bronchoscopy with BAL in stable adult patients with cystic fibrosis Aridgides, Daniel Dessaint, John Atkins, Graham Carroll, James Ashare, Alix PLoS One Research Article Data on adverse events from research bronchoscopy with bronchoalveolar lavage (BAL) in patients with cystic fibrosis (CF) is lacking. As research bronchoscopy with BAL is useful for isolation of immune cells and investigation of CF lung microbiome, we sought to investigate the safety of bronchoscopy in adult patients with CF. Between November 2016 and September 2019, we performed research bronchoscopies on CF subjects (32) and control subjects (82). Control subjects were nonsmokers without respiratory disease. CF subjects had mild or moderate obstructive lung disease (FEV(1) > 50% predicted) and no evidence of recent CF pulmonary exacerbation. There was no significant difference in the age or sex of each cohort. Neither group experienced life threatening adverse events. The number of adverse events was similar between CF and control subjects. The most common adverse events were sore throat and cough, which occurred at similar frequencies in control and CF subjects. Fever and headache occurred more frequently in CF subjects. However, the majority of fevers were seen in CF subjects with FEV(1) values below 65% predicted. We found that CF subjects had similar adverse event profiles following research bronchoscopy compared to healthy subjects. While CF subjects had a higher rate of fevers, this adverse event occurred with greater frequency in CF subjects with lower FEV(1). Our data demonstrate that research bronchoscopy with BAL is safe in CF subjects and that safety profile is improved if bronchoscopies are limited to subjects with an FEV(1) > 65% predicted. Public Library of Science 2021-01-22 /pmc/articles/PMC7822334/ /pubmed/33481845 http://dx.doi.org/10.1371/journal.pone.0245696 Text en © 2021 Aridgides et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Aridgides, Daniel
Dessaint, John
Atkins, Graham
Carroll, James
Ashare, Alix
Safety of research bronchoscopy with BAL in stable adult patients with cystic fibrosis
title Safety of research bronchoscopy with BAL in stable adult patients with cystic fibrosis
title_full Safety of research bronchoscopy with BAL in stable adult patients with cystic fibrosis
title_fullStr Safety of research bronchoscopy with BAL in stable adult patients with cystic fibrosis
title_full_unstemmed Safety of research bronchoscopy with BAL in stable adult patients with cystic fibrosis
title_short Safety of research bronchoscopy with BAL in stable adult patients with cystic fibrosis
title_sort safety of research bronchoscopy with bal in stable adult patients with cystic fibrosis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7822334/
https://www.ncbi.nlm.nih.gov/pubmed/33481845
http://dx.doi.org/10.1371/journal.pone.0245696
work_keys_str_mv AT aridgidesdaniel safetyofresearchbronchoscopywithbalinstableadultpatientswithcysticfibrosis
AT dessaintjohn safetyofresearchbronchoscopywithbalinstableadultpatientswithcysticfibrosis
AT atkinsgraham safetyofresearchbronchoscopywithbalinstableadultpatientswithcysticfibrosis
AT carrolljames safetyofresearchbronchoscopywithbalinstableadultpatientswithcysticfibrosis
AT asharealix safetyofresearchbronchoscopywithbalinstableadultpatientswithcysticfibrosis